| abstract |
The present invention relates to a novel oral dosage unit comprising the antidepressant mytazapine as an active ingredient, wherein the dosage unit is of the orally-disintegrating type. The dosage unit disintegrates rapidly upon oral administration and is bioequivalent to conventional tablets, but may be advantageous in view of side effects, effects, sleep enhancing effects and initiation of action. |